Atlas Trials

Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

Clinical trial NCT07454837 · RECRUITING

Trial details

NCT number
NCT07454837
Sponsor
Mirum Pharmaceuticals, Inc.
Status
RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Chronic Hepatitis D
Start date
2026-02-26
Primary completion
2027-08-31
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.